Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: Today's fit-focused travelers want to pair exercise with escapades and fitness with fun, whether it's yoga among the sea turtles, bootcamp on the beach or a zumba cruise. "Fitness retreat used to mean go away and lose weight," said Melisse Gelula, co-founder of the wellness media company Well+Good. "Now it's just working fitness into a schedule that might also include lavish dinners, beach time, cocktail hours, nights out dancing." Wellness tourism, which includes travel paired with activities such as yoga retreats, fitness centers, boot camps, cycling, gyms and other activities, is about a $500 billion global market, according to The Global Wellness Tourism Economy report of 2013. The report said wellness tourism represents 14 percent of total global tourism revenues overall and is projected to rise to 16 percent by 2017. In January, Royal Caribbean Cruises Ltd will launch its first ever Zumba Cruise, offering all-day classes in the popular Latin American dance-based aerobic program during a cruise that will leave from Fort Lauderdale in Florida and make stops in Jamaica and Haiti. Daily classes will be led by 130 zumba instructors. "Our focus is more fun," said Allison Robins of the global lifestyle brand Zumba Fitness, which is working with the cruise line. "You'll never see us talking about weight loss, although that just happens." Maria Walker, founder of Getaway Fitness in Florida which offers workout vacations in Florida and California, refers to the growing industry as fitness adventure. "When I started, there were spa resorts and fat camps but not much in the middle," said Walker, whose clients are mostly people in their 30s, 40s and 50s. Now activities range from boot camp and rock climbing to kayaking, and discussions focus more on exercise and nutrition than weight loss. YogaWorks, the national chain of yoga studios, offers 10 to 15 retreats a year and plans to scale up offerings in 2016. "It's definitely a growing part of the business," said spokesperson Kim Allardyce, adding it is not just about perfecting one's yoga postures. Although the emphasis is on yoga, depending on where the tour is, local sites are also included. In Costa Rica vacationers might help release sea turtles and in Italy go on wine-tasting excursions. The goal, she said, is to marry fitness with an experience specific to the location.
[A]: Fitness vacations favor fun, adventure over weight loss.

[Q]: While there was no mention of coffee cost, this element is not particulary germane to this story. The article reported that drinking four eight-ounce cups of coffee was linked to a 30% reduction in the risk of developing diabetes. Rather than relative reduction, the article should have included the absolute reduction. The rate at which women who drank coffee developed type II diabetes was 6.05% while the rate in women who drank 4-5 cups of coffee per day was 4.30%. The relative difference always sounds more convincing; the absolute difference is what is probably most meaningful to viewers. So, in this case, a 30% relative difference equated to an absolute difference of less than 2%. There was no mention of potential harms that might be derived from increased coffee consumption. The article could have included concern about disrupted sleep, heart palpitations, increased urinary frequency, and jitteriness. Because of the design of the study covered in this story (a prospective epidemiologic study), it is not possible to conclude that increasing decaffeinated coffee consumption will decrease the risk of type II diabetes. This important point was covered by one of the physician quotes in the story. The speculation about what was in decaf coffee that resulted in the decreased risk of type II diabetes was not well grounded. Other than painting perhaps a little too rosy picture of all the potential benefits that might be gained from coffee consumption, this article did not practice disease mongering. It did not present any data on the prevalence of type II diabetes. The story could have mentioned that the Type II diabetes has become rather common place and is a public health issue. It appears that this story is based on a research study in the Archives of Internal Medicine and from comments by one physician and one researcher. It certainly would have been better to actually mention where the study was published rather than referring to it as "the study out today". It would also have been better to give us some perspective about the value of the quotes provided by giving some background on the two people interviewed. Nonethless, we credit the story for having different perspectives. There was no mention of other lifestyle strategies that an individual might pursue in order to lower the risk of type II diabetes. This is a particularly important public health message. Moderate daily physical activity, such as walking, has also been shown to lower the risk of type II diabetes. The story isn't about a treatment per se, but about the effects of drinking coffee, which is readily available to all. The story is quite clear about the widespread availability and use of coffee. There is a growing body of literature suggesting that coffee drinking can lower one's risk of type II diabetes. This story covered the latest such evidence, and made it clear that this is part of a growing body of "more intriguing evidence." There is no evidence that this story relied solely or largely on a news release.
[A]: Coffee found to reduce risk of diabetes

[Q]: Excellent job here. The costs of treatment are a core aspect of the story. The opening paragraph describes how the blood test in question could help determine whether patients should receive "costly new-generation drugs or rely on much cheaper traditional chemotherapy," and the specific costs of different therapies are detailed early in the article. Much less information is given about the cost of the blood test itself, though the writer does make it clear that the price is not yet determined. It would have beenuseful to note the costs ofanycomparabletests already in clinical use, and tolet the reader know how insurance companies deal withnew diagnostic tests. The story says "in a study published last month, patients who tested positive for the anomalya variant of the androgen receptor called AR-V7lived substantially longer if they were treated with chemotherapy than those given the two new drugs." However, the story doesn't provide specifics on what that means in number terms. The story does not explain harms. However, diagnostic tests are only as good as their sensitivity and reliability, so it would have been good for readers to get an impression of whether the test catches every case of AR-V7, and the likelihood of false positives or false negatives. Even if that information is not yet available, it is important for readers to be made aware of the issue that a false result could lead to the wrong therapy being given. The storylets us known that this was arelatively small study of 161 patients, and it is described as "retrospective." We're also told that the blood test needs validation in large randomized controlled trials. While it may be challenging for readers not well-versed in study design to discernwhat the limitations of a retrospective study is, and what further information a randomized trial would deliver, these details are sufficient enough to rate Satisfactory. We also appreciated these words of caution:"In the study, a positive test for AR-V7 didn't assure patients would respond to the chemotherapy, nor did a negative test promise a response to the Xtandi or Zytiga." Advanced stage prostate cancer is a common, life-threatening disease. The article gives an estimate, albeit from the companies behind the test, that 50,000U.S. men with advanced prostate cancer would be candidates for the test. No independent expert source is quoted throughout the story. This is problematic not least because representatives of both Epic Sciences and Genomic Health are quoted on the clinical utility of the test, and their claims need to bevalidated or refuted by experts with no skin in the game. It would also be important to get an independent take on the study itself, the strength of the evidence andwhether there were any limitations that should be highlighted. Additionally, next to no information is given about conflicts of interest. While the lead author's affiliation isgiven as Memorial Sloan-Kettering Cancer Center, the majority of co-authors of the study are employees of Epic Sciences. This surely warrants a mention so readers are not given the false impression that the company had no role in the study. Moreover, the lead author Howard Scher has received research funding, personal fees and non-financial support from all the companies behindthe prostate cancer drugs in question. Despite the fact that the blood test would theoretically identify patients who would be better offnot receiving the drugs, Scher has highly relevant conflicts of interest, thus increasing the need for independent expert sources. The article does not explicitly describe whether there are other methods of detecting AR-V7, though it is implicit that AR-V7 has not been used clinically as a biomarker before, and two other companies developing a similar test are mentioned. Thestory is based around whether using AR-V7 as a biomarker could lead to better outcomes thancurrent clinical standards, so the comparison to the "status-quo" alternative is thoroughly explored. It is made clear that the blood test is not currently available, and the article gives a prospective date forwhen the test will be launched. Since AR-V7 is not currently used as a biomarker for treatment of advanced prostate cancer, it is clear enough to the reader that this is a new approach. An important point that is only mentioned in passingis that the test is a "liquid biopsy." Liquid biopsies haveoften been hyped as a revolutionary new approach to diagnosing cancer without invasive procedures. However, due to questions over sensitivity and reliability, they have been controversial and are yet to become commonplace in clinical practice, so readers might have benefited from a little more context on this point. The writerhas clearly interviewed his sources and included substantially more information than available from news releases by either Epic Sciences or Genomic Health.
[A]:
Test Aids Prostate Cancer Treatment